The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
The natural course of hypermutator gliomas.
 
Carlos Kamiya-Matsuoka
No Relationships to Disclose
 
Nicholas Robert Metrus
No Relationships to Disclose
 
Kenna Rael Shaw
No Relationships to Disclose
 
Marta Penas-Prado
Consulting or Advisory Role - AGIOS; Lilly
Research Funding - Abbvie (Inst); Agios (Inst); AROG (Inst); DelMar Pharmaceuticals (Inst); DNAtrix (Inst); EMD Serono (Inst); Genentech/Roche (Inst); Novartis (Inst); Orbus Therapeutics (Inst)
 
Shiao-Pei S. Weathers
No Relationships to Disclose
 
Monica Elena Loghin
No Relationships to Disclose
 
Kristin Alfaro-Munoz
Consulting or Advisory Role - Abbvie
 
Ying Yuan
Honoraria - Ono Pharmaceutical
Consulting or Advisory Role - Juno Therapeutics
 
Barbara Jane O'Brien
Honoraria - Monteris Medical
Consulting or Advisory Role - Abbvie
Travel, Accommodations, Expenses - Kadmon
 
Rebecca A. Harrison
No Relationships to Disclose
 
W. K. Alfred Yung
Honoraria - Amgen; DNAtrix
Consulting or Advisory Role - Amgen; DNAtrix
 
Funda Meric-Bernstam
Honoraria - Dialectica; Sumitomo Group
Consulting or Advisory Role - Clearlight Diagnostics; DarwinHealth; Genentech; GRAIL; Inflection Biosciences; Pieris Pharmaceuticals; Samsung Bioepis
Research Funding - Abbvie; Aileron Therapeutics; AstraZeneca; Bayer; Calithera Biosciences; Curis; CytomX Therapeutics; Debiopharm Group; eFFECTOR Therapeutics; Genentech; Jounce Therapeutics; Novartis; Pfizer; PUMA Biotechnology; Taiho Pharmaceutical; Zymeworks
 
John Frederick De Groot
Employment - Helsinn Therapeutics (I); ZIOPHARM Oncology (I)
Leadership - ZIOPHARM Oncology (I)
Stock and Other Ownership Interests - Gilead Sciences; ZIOPHARM Oncology (I)
Consulting or Advisory Role - Abbvie; AstraZeneca; Boston Biomedical; CarThera; Celldex; Deciphera; Five Prime Therapeutics; Foundation Medicine; Genentech/Roche; GW Pharmaceuticals; Insys Therapeutics; Kadmon; Merck; Novogen; Omniox; Oxigene; Vascular Biogenics
Research Funding - Deciphera; EMD Serono; Lilly; Mundipharma; Novartis; Sanofi
Patents, Royalties, Other Intellectual Property - AstraZeneca - Research Support; Deciphera Pharmaceuticals - Research Support; Eli Lilly - Research Support; EMD-Serono - Research Support; Novartis - Research Support; Sanofi-Aventis - Research Support